Use of bone morphogenetic proteins for augmentation of bone regeneration

Journal of the American Veterinary Medical Association

Volumn 231, Issue 7, 2007, Pages 1039-1055

  Kirker Head, Carl A ^a   Boudrieau, Randy T ^a   Kraus, Karl H ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL; ANIMAL DISEASE; BONE DEVELOPMENT; BONE TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECT; FRACTURE HEALING; METHODOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; FRACTURE HEALING; OSTEOGENESIS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 35548969847     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.231.7.1039     Document Type: Review

References (154)

1. Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: an update. Injury 2005;36(suppl 3):S20-S27.
2. Einhorn TA. Clinical applications of recombinant human BMPs: early experience and future development. J Bone Joint Surg Am 2003;85-A(suppl 3):82-88.
3. Reddi AH, Marshall R. Urist: a renaissance scientist and orthopaedic surgeon. J Bone Joint Surg Am 2003;85-A:3-7.
4. Sampath T, Reddi H. Bone morphogenetic protein (BMP) implants as bone graft substitutes-promises and challenges. In: Laurencin CT, ed. Bone graft substitutes. West Conshohocken, Pa: ASTM International & American Academy of Orthopaedic Surgeons, 2003;194-213.
5. Urist MR, Strates BS. Bone morphogenetic protein. J Dent Res 1971;50:1392-1406.
6. Kirker-Head CA. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev 2000;43:65-92.
7. Johnson EE, Marshall R, Urist MR. Resistant nonunions and partial or complete segmental defects of long bones. Treatment with implants of a compostie of human bone morphogenetic protein (BMP) and autolyzed, antigenextracted, allogeneic (AAA) bone. Clin Orthop Relat Res 1992;277:229-237.
8. Johnson EE, Urist MR, Finerman GA. Bone morphogenetic protein augmentation grafting of resistant femoral nonunions. A preliminary report. Clin Orthop Relat Res 1988;230:257-265.
9. Johnson EE, Urist MR, Finerman GA. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. Clin Orthop Relat Res 1988;236:249-257.
10. Kujala S, Raatikainen T, Ryhanen J, et al. Composite implant of native bovine bone morphogenetic protein (BMP), collagen carrier and biocoral in the treatment of resistant ulnar non-unions: report of five preliminary cases. Arch Orthop Trauma Surg 2004;124:26-30.
11. Vallejo LF, Brokelmann M, Marten S, et al. Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. J Biotechnol 2002;94:185-194.
12. Southwood LL, Frisbie DD, Kawcak CE, et al. Delivery of growth factors using gene therapy to enhance bone healing. Vet Surg 2004;33:565-578.
13. European Agency for the Evaluation of Medicinal Products. Dibotermin alfa. Scientific discussion. European Public Assessment Record. Available at: www.emea.europa.eu/humandocs/pdfs/ EPAR/inductos/318802en6.pdf. Accessed Sep 10, 2007.
14. Samartzis D, Khanna N, Shen FH, et al. Update on bone morphogenetic proteins and their application in spine surgery. J Am Coll Surg 2005;200:236-248.
15. Lianjia Y, Yan J. Immunohistochemical observations on bone morphogenetic protein in normal and abnormal conditions. Clin Orthop Relat Res 1990;257:249-256.
16. Sakou T. Bone morphogenetic proteins: from basic studies to clinical approaches, Bone 1998;22:591-603.
17. Bostrom MP. Expression of bone morphogenetic proteins in fracture healing. Clin Orthop Relat Res 1998;(suppl 355):S116-S123.
18. Cheng H, Jiang W, Phillips FM, et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 2003;85-A:1544-1552.
19. Ferguson CM, Miclau T, Hu D, et al. Common molecular pathways in skeletal morphogenesis and repair. Ann N Y Acad Sci 1998;857:33-42.
20. Karsenty G. Genetics of skeletogenesis. Dev Genet 1998;22:301-313.
21. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998;16:247-252.
22. Irie K, Alpaslan C, Takahashi K, et al. Osteoclast differentiation in ectopic bone formation induced by recombinant human bone morphogenetic protein 2 (rhBMP-2). J Bone Miner Metab 2003;21:363-369.
23. Ganan Y, Macias D, Duterque-Coquillaud M, et al. Role of TGF beta s and BMPs as signals controlling the position of the digits and the areas of interdigital cell death in the developing chick limb autopod. Development 1996;122:2349-2357.
24. Zou H, Niswander L. Requirement for BMP signaling in interdigital apoptosis and scale formation. Science 1996;272:738-741.
25. Barth KA, Kishimoto Y, Rohr KB, et al. BMP activity establishes a gradient of positional information throughout the entire neural plate. Development 1999;126:4977-4987.
26. Farkas LM, Jaszai J, Unsicker K, et al. Characterization of bone morphogenetic protein family members as neurotrophic factors for cultured sensory neurons. Neuroscience 1999;92:227-235.
27. Mabie PC, Mehler MF, Kessler JA. Multiple roles of bonemorphogenetic protein signaling in the regulation of cortical cell number and phenotype. J Neurosci 1999;19:7077-7088.
28. Mehler MF, Mabie PC, Zhang D, et al. Bone morphogenetic proteins in the nervous system. Trends Neurosci 1997;20:309-317.
29. Keshishian H, Kim YS. Orchestrating development and function: retrograde BMP signaling in the Drosophila nervous system. Trends Neurosci 2004;27:143-147.
30. Mohan RR, Kim WJ, Mohan RR, et al. Bone morphogenic proteins 2 and 4 and their receptors in the adult human cornea. Invest Ophthalmol Vis Sci 1998;39:2626-2636.
31. You L, Kruse FE, Pohl J, et al. Bone morphogenetic proteins and growth and differentiation factors in the human cornea. Invest Ophthalmol Vis Sci 1999;40:296-311.
32. Peters H, Balling R. Teeth. Where and how to make them. Trends Genet 1999;15:59-65.
33. Harris SE, Harris MA, Mahy P, et al. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-211.
34. Shimasaki S, Zachow RJ, Li D, et al. A functional bone morphogenetic protein system in the ovary. Proc Natl Acad Sci U S A 1999;96:7282-7287.
35. Weaver M, Yingling JM, Dunn NR, et al. Bmp signaling regulates proximal-distal differentiation of endoderm in mouse lung development. Development 1999;126:4005-4015.
36. Ozkaynak E, Schnegelsberg PN, Oppermann H. Murine osteogenic protein (OP-1): high levels of mRNA in kidney. Biochem Biophys Res Commun 1991;179:116-123.
37. Croteau S, Rauch F, Silvestri A, et al. Bone morphogenetic proteins in orthopedics: from basic science to clinical practice. Orthopedics 1999;22:686-695.
38. Sampath TK, Rashka KE, Doctor JS, et al. Drosophila transforming growth factor beta superfamily proteins induce endochondral bone formation in mammals. Proc Natl Acad Sci U S A 1993;90:6004-6008.
39. Hayward DC, Samuel G, Pontynen PC, et al. Localized expression of a dpp/BMP2/4 ortholog in a coral embryo. Proc Natl Acad Sci U S A 2002;99:8106-8111.
40. Wozney JM, Rosen V Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 1998;346:26-37.
41. Sampath TK, Coughlin JE, Whetstone RM, et al. Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. J Biol Chem 1990;265:13198-13205.
42. Cheung E, Katti D, Rosier R, et al. Review of state of the art: growth factor based systems for use as bone graft substitutes. In: Laurencin C, ed. Bone graft substitutes. West Conshohocken, Pa: ASTM International & the American Academy of Orthopaedic Surgeons, 2003;174-193.
43. Arteaga-Solis E, Gayraud B, Lee SY, et al. Regulation of limb patterning by extracellular microfibrils. J Cell Biol 2001;154:275-281.
44. Larrain J, Oelgeschlager M, Ketpura NI, et al. Proteolytic cleavage of Chordin as a switch for the dual activities of Twisted gastrulation in BMP signaling. Development 2001;128:4439-4447.
45. Ohkawara B, Iemura S, ten Dijke P, et al. Action range of BMP is defined by its N-terminal basic amino acid core. Curr Biol 2002;12:205-209.
46. Rosen V BMP and BMP inhibitors in bone. Ann N Y Acad Sci 2006;1068:19-25.
47. Wan M, Cao X. BMP signaling in skeletal development. Biochem Biophys Res Commun 2005;328:651-657.
48. Tsuji K, Bandyopadhyay A, Harfe BD, et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006;38:1424-1429.
49. Bandyopadhyay A, Tsuji K, Cox K, et al. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeleto-genesis. PLoS Genet 2006;2:e216.
50. Nilsson O, Parker EA, Hegde A, et al. Gradients in bone morphogenetic protein-related gene expression across the growth plate. J Endocrinol 2007;193:75-84.
51. Minina E, Schneider S, Rosowski M, et al. Expression of Fgf and Tgfbeta signaling related genes during embryonic endochondral ossification. Gene Expr Patterns 2005;6:102-109.
52. Kobayashi T, Lyons KM, McMahon AP, et al. BMP signaling stimulates cellular differentiation at multiple steps during cartilage development. Proc Natl Acad Sci U S A 2005;102:18023-18027.
53. Urist MR, Hudak RT. Radioimmunoassay of bone morphogenetic protein in serum: a tissue-specific parameter of bone metabolism. Proc Soc Exp Biol Med 1984;176:472-475.
54. Einhorn TA. Clinical applications of recombinant gene technology: bone and cartilage repair. Cells Mater 1992;2:1-11.
55. Turgeman G, Zilberman Y, Zhou S, et al. Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J Cell Biochem 2002;86:461-474.
56. Maric I, Poljak L, Zoricic S, et al. Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats. J Cell Physiol 2003;196:258-264.
57. Lefer AM, Tsao PS, Ma XL, et al. Anti-ischaemic and endothelial protective actions of recombinant human osteogenic protein (hOP-1). J Mol Cell Cardiol 1992;24:585-593.
58. Chang CF, Lin SZ, Chiang YH, et al. Intravenous administration of bone morphogenetic protein-7 after ischemia improves motor function in stroke rats. Stroke 2003;34:558-564.
59. Niksic L, Martin PY. BMP-7 (Bone morphogenetic protein-7): a future treatment for chronic renal failure? [in French]. Rev Med Suisse 2005;1:568-570, 572-573.
60. Alden TD, Varady P, Kallmes DF, et al. Bone morphogenetic protein gene therapy. Spine 2002;27:S87-S93.
61. Niyibizi C, Baltzer A, Lattermann C, et al. Potential role for gene therapy in the enhancement of fracture healing. Clin Orthop Relat Res 1998;(suppl 355):S148-S153.
62. Chen Y. Orthopedic applications of gene therapy. J Orthop Sci 2001;6:199-207.
63. Goldstein SA, Bonadio J. Potential role for direct gene transfer in the enhancement of fracture healing. Clin Orthop Relat Res 1998;(suppl 355):S154-S162.
64. Fang J, Zhu YY, Smiley E, et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci U S A 1996;93:5753-5758.
65. Zhang YP, Sekirov L, Saravolac EG, et al. Stabilized plasmidlipid particles for regional gene therapy: formulation and transfection properties. Gene Ther 1999;6:1438-1447.
66. Musgrave DS, Bosch P, Lee JY, et al. Ex vivo gene therapy to produce bone using different cell types. Clin Orthop Relat Res 2000;378:290-305.
67. Lieberman JR, Le LQ, Wu L, et al. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998;16:330-339.
68. Lou J, Xu F, Merkel K, et al. Gene therapy: adenovirus-mediated human bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo. J Orthop Res 1999;17:43-50.
69. Gazit D, Turgeman G, Kelley P, et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1999;1:121-133.
70. Wright V, Peng H, Usas A, et al. BMP4-expressing musclederived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. Mol Ther 2002;6:169-178.
71. Bertone AL, Pittman DD, Bouxsein ML, et al. Adenoviral-mediated transfer of human BMP-6 gene accelerates healing in a rabbit ulnar osteotomy model. J Orthop Res 2004;22:1261-1270.
72. Lieberman JR, Daluiski A, Stevenson S, et al. The effect of regional gene therapy with bone morphogenetic proteins-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint SurgAm 1999;81:905-917.
73. Baltzer AW, Lattermann C, Whalen JD, et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 2000;7:734-739.
74. Einhorn TA, Majeska RJ, Mohaideen A, et al. A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair. J Bone Joint Surg Am 2003;85-A:1425-1435.
75. Winn SR, Uludag H, Hollinger JO. Carrier systems for bone morphogenetic proteins. Clin Orthop Relat Res 1999;(suppl 367):S95-S106.
76. Cook SD, Baffes GC, Wolfe MW, et al. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop Relat Res 1994;301:302-312.
77. Welch RD, Jones AL, Bucholz RW, et al. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 1998;13:1483-1490.
78. De Groot J. Carriers that concentrate native bone morphogenetic protein in vivo. Tissue Eng 1998;4:337-341.
79. Seeherman H, Li R, Wozney J. A review of preclinical program development for evaluating injectable carriers for osteogenic factors. J Bone Joint Surg Am 2003;85-A(suppl 3):96-108.
80. Gerhart TN, Kirker-Head CA, Kriz MJ, et al. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop Relat Res 1993;293:317-326.
81. Kirker-Head CA, Gerhart TN, Schelling SH, et al. Long-term healing of bone using recombinant human bone morphogenetic protein 2. Clin Orthop Relat Res 1995;318:222-230.
82. Vail TB, Trotter GW, Powers BE. Equine demineralized bone matrix: relationship between particle size and osteoinduction. Vet Surg 1994;23:386-395.
83. Takaoka K, Koezuka M, Nakahara H. Telopeptide-depleted bovine skin collagen as a carrier for bone morphogenetic protein. J Orthop Res 1991;9:902-907.
84. Strong MD, Sayers MH, Conrad EU. Screening tissue donors for infectious markers. In: Friedlaender GE, Goldberg VM, eds. Bone and cartilage allografts. Park Ridge, Ill: American Academy of Orthopedic Surgeons, 1989;193-211.
85. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 2003;55:1613-1629.
86. Friess W, Uludag H, Foskett S, et al. Characterization of absorbable collagen sponges as recombinant human bone morphogenetic protein-2 carriers. Int J Pharm 1999;185:51-60.
87. Seeherman H, Wozney JM. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev 2005;16:329-345.
88. Yang C, Hillas PJ, Baez JA, et al. The application of recombinant human collagen in tissue engineering. BioDrugs 2004; 18:103-119.
89. Sofia S, McCarthy MB, Gronowicz G, et al. Functionalized silk-based biomaterials for bone formation. J Biomed Mater Res 2000;54:139-148.
90. Meinel L, Hofmann S, Karageorgiou V, et al. The inflammatory responses to silk films in vitro and in vivo. Biomaterials 2005;26:147-155.
91. Meinel L, Betz O, Fajardo R, et al. Silk based biomaterials to heal critical sized femur defects. Bone 2006;39:922-931.
92. Kirker-Head C, Karageorgian V, Hofmann S, et al. BMP-silk composite matrices heal critically sized femoral defects. Bone 2007;41:247-255.
93. Kirker-Head CA, Gerhart TN, Armstrong R, et al. Healing bone using recombinant human bone morphogenetic protein 2 and copolymer. Clin Orthop Relat Res 1998;349:205-217.
94. Wang Y, Kim YM, Langer R. In vivo degradation characteristics of poly(glycerol sebacate). J Biomed Mater Res A 2003;66: 192-197.
95. Saito N, Okada T, Horiuchi H, et al. Local bone formation by injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers. Bone 2003;32:381-386.
96. Bulpitt P, Aeschlimann D. New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels. J Biomed Mater Res 1999;47:152-169.
97. Hong L, Tabata Y, Yamamoto M, et al. Comparison of bone regeneration in a rabbit skull defect by recombinant human BMP-2 incorporated in biodegradable hydrogel and in solution. J Biomater Sci Polym Ed 1998;9:1001-1014.
98. Yamamoto M, Tabata Y, Ikada Y. Ectopic bone formation induced by biodegradable hydrogels incorporating bone morphogenetic protein. J Biomater Sci Polym Ed 1998;9:439-458.
99. Yamamoto M, Takahashi Y, Tabata Y. Enhanced bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng 2006;12:1305-1311.
100. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 2005;23:47-55.
101. Lutolf MP, Weber FE, Schmoekel HG, et al. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol 2003;21:513-518.
102. Wozney JM, Li RH. Engineering what comes naturally. Nat Biotechnol 2003;21:506-508.
103. Lindholm TS, Gao TJ. Functional carriers for bone morphogenetic proteins. Ann Chir Gynaecol Suppl 1993;207:3-12.
104. Edwards RB 3rd, Seeherman HJ, Bogdanske JJ, et al. Percutaneous injection of recombinant human bone morphogenetic protein-2 in a calcium phosphate paste accelerates healing of a canine tibial osteotomy. J Bone Joint Surg Am 2004;86-A:1425-1438.
105. Akamaru T, Suh D, Boden SD, et al. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine 2003;28:429-434.
106. Spiro RC, Liu L, Heidaran MA, et al. Inductive activity of recombinant human growth and differentiation factor-5, Biochem Soc Trans 2000;28:362-368.
107. Jahng TA, Fu TS, Cunningham BW, et al. Endoscopic instrumented posterolateral lumbar fusion with Healos and recombinant human growth/differentiation factor-5. Neurosurgery 2004;54:171-180.
108. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84-A:2123-2134.
109. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial non-unions. J Bone Joint Surg Am 2001;83-A(suppl 1):S151-S158.
110. den Boer FC, Bramer JA, Blokhuis TJ, et al. Effect of recombinant human osteogenic protein-1 on the healing of a freshly closed diaphyseal fracture. Bone 2002;31:158-164.
111. Bouxsein ML, Turek TJ, Blake CA, et al. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am 2001;83-A:1219-1230.
112. Faria ML, Lu Y, Heaney K, et al. Recombinant human bone morphogenetic protein-2 in absorbable collagen sponge enhances bone healing of tibial osteotomies in dogs. Vet Surg 2007;36:122-131.
113. Paatsama S, Lindholm S, OksanenJ, et al. The use of bone morphogenetic proteins in delayed fracture healing, pseudoarthrosis and in ulna osteotomy carried out because of elbow joint diseases [in German]. Tierarztl Prax 1996;24:164-168.
114. Itoh T, Mochizuki M, Fuda K, et al. Femoral nonunion fracture treated with recombinant human bone morphogenetic protein-2 in a dog. J Vet Med Sci 1998;60:535-538.
115. Hong H. Ulnar radial nonunion fracture treated with recombinant human bone morphogenetic protein-2 in a dog. J Vet Clin (Seoul) 2001;18:156-159.
116. Schmokel HG, Weber FE, Seiler G, et al. Treatment of non-unions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix. Vet Surg 2004;33:112-118.
117. Milovancev M, Muir P, Manley PA, et al. Clinical application of recombinant human bone morphogenetic protein-2 in 4 dogs. Vet Surg 2007;36:132-140.
118. Shen HC, Peng H, Usas A, et al. Structural and functional healing of critical-size segmental bone defects by transduced muscle-derived cells expressing BMP4. J Gene Med 2004;6:984-991.
119. Dzugan S, Galjour C, Conflitti J, et al. Sustained release of OP-1 and antibiotics in treatment of femoral defects in male rats. Biomed Sci Instrum 2005;41:80-85.
120. Hu YY, Zhang C, Lu R, et al. Repair of radius defect with bone-morphogenetic-protein loaded hydroxyapatite/collagen-poly (L-lactic acid) composite. Chin J Traumatol 2003;6:67-74.
121. Dai KR, Xu XL, Tang TT, et al. BMP-2 gene modified tissue-engineered bone repairing segmental tibial bone defects in goats [in Chinese]. Zhonghua Yi Xue Za Zhi 2003;83:1345-1349.
122. Kokubo S, Fujimoto R, Yokota S, et al. Bone regeneration by recombinant human bone morphogenetic protein-2 and a novel biodegradable carrier in a rabbit ulnar defect model. Biomaterials 2003;24:1643-1651.
123. Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 1999;81:710-718.
124. Riew KD, Lou J, Wright NM, et al. Thoracoscopic intradiscal spine fusion using a minimally invasive gene-therapy technique. J Bone Joint Surg Am 2003;85-A:866-871.
125. Campisi P, Hamdy RC, Lauzier D, et al. Expression of bone morphogenetic proteins during mandibular distraction osteogenesis. Plast Reconstr Surg 2003;111:201-208, discussion 209-210.
126. Kraiwattanapong C, Boden SD, Louis-Ugbo J, et al. Comparison of Healos/bone marrow to INFUSE(rhBMP-2/ACS) with a collagen-ceramic sponge bulking agent as graft substitutes for lumbar spine fusion. Spine 2005;30:1001-1007.
127. Arosarena OA, Falk A, Malmgren L, et al. Defect repair in the rat mandible with bone morphogenic proteins and marrow cells. Arch Facial Plast Surg 2003;5:103-108.
128. Park J, Ries J, Gelse K, et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 2003;10:1089-1098.
129. Sun Y, Ma G, Li D. Repair of large cranial defect using allogeneic cranial bone and bone morphogenetic protein [in Chinese]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1995;11:8-9.
130. Ma G, Zhu XZ, Clinical observation on repair of bone defects in maxillofacial region by grafting hydroxylapatite combined with porcine bone morphogenetic protein [in Chinese]. Zhonghua Kou Qiang Yi Xue Za Zhi 1994;29:223-225.
131. Sailer HF, Kolb E. Application of purified bone morphogenetic protein (BMP) in cranio-maxillo-facial surgery. BMP in compromised surgical reconstructions using titanium implants. J Craniofac Surg 1994;22:2-11.
132. Moghadam HG, Urist MR, Sandor GK, et al. Successful mandibular reconstruction using a BMP bioimplant. J Craniofac Surg 2001;12:119-127.
133. Boudrieau RJ, Mitchell SL, Seeherman H. Mandibular reconstruction of a partial hemimandibulectomy in a dog with severe malocclusion. Vet Surg 2004;33:119-130.
134. Kawamoto T, Motohashi N, Kitamura A, et al. Experimental tooth movement into bone induced by recombinant human bone morphogenetic protein-2. Cleft Palate Craniofac J 2003;40:538-543.
135. Jin QM, Anusaksathien O, Webb SA, et al. Gene therapy of bone morphogenetic protein for periodontal tissue engineering. J Periodontal 2003;74:202-213.
136. Takahashi D, Odajima T, Morita M, et al. Formation and resolution of ankylosis under application of recombinant human bone morphogenetic protein-2 (rhBMP-2) to class III furcation defects in cats. J Periodontal Res 2005;40:299-305.
137. Wikesjo UM, Xiropaidis AV, Thomson RC, et al. Periodontal repair in dogs: rhBMP-2 significantly enhances bone formation under provisions for guided tissue regeneration. J Clin Periodontol 2003;30:705-714.
138. Wikesjo UM, Qahash M, Thomson RC, et al. rhBMP-2 significantly enhances guided bone regeneration. Clin Oral Implants Res 2004;15:194-204.
139. Jovanovic SA, Hunt DR, Bernard GW, et al. Long-term functional loading of dental implants in rhBMP-2 induced bone. A histologic study in the canine ridge augmentation model. Clin Oral Implants Res 2003;14:793-803.
140. Wikesjo UM, Sorensen RG, Kinoshita A, et al. Periodontal repair in dogs: effect of recombinant human bone morphogenetic protein-12 (rhBMP-12) on regeneration of alveolar bone and periodontal attachment. J Clin Periodontal 2004;31:662-670.
141. Sorensen RG, Polimeni G, Kinoshita A, et al. Effect of recombinant human bone morphogenetic protein-12 (rhBMP-12) on regeneration of periodontal attachment following tooth replantation in dogs. J Clin Periodontal 2004;31:654-661.
142. Saito E, Saito A, Kawanami M. Favorable healing following space creation in rhBMP-2-induced periodontal regeneration of horizontal circumferential defects in dogs with experimental periodontitis. J Periodontal 2003;74:1808-1815.
143. Kirker-Head CA, Nevins M, Palmer R, et al. A new animal model for maxillary sinus floor augmentation: evaluation parameters. Int J Oral Maxillofac Implants 1997;12:403-411.
144. Jung RE, Glauser R, Scharer P, et al. Effect of rhBMP-2 on guided bone regeneration in humans. Clin Oral Implants Res 2003;14:556-568.
145. Bragdon CR, Doherty AM, Rubash HE, et al. The efficacy of BMP-2 to induce bone in growth in a total hip replacement model. Clin Orthop Relat Res 2003;417:50-61.
146. Barrack RL, Cook SD, Patron LP, et al. Induction of bone ingrowth from acetabular defects to a porous surface with OP-1. Clin Orthop Relat Res 2003;417:41-49.
147. Soballe K, Jensen TB, Mouzin O, et al. Differential effect of a bone morphogenetic protein-7 (OP-1) on primary and revision loaded, stable implants with allograft. J Biomed Mater Res A 2004;71:569-576.
148. Yazawa M, Kishi K, Nakajima H, et al. Expression of bone morphogenetic proteins during mandibular distraction osteogenesis in rabbits. J Oral Maxillofac Surg 2003;61:587-592.
149. Farhadieh RD, Gianoutsos MP, Yu Y, et al. The role of bone morphogenetic proteins BMP-2 and BMP-4 and their related postreceptor signaling system (Smads) in distraction osteogenesis of the mandible. J Craniofac Surg 2004;15:714-718.
150. Mizumoto Y, Moseley T, Drews M, et al. Acceleration of regenerate ossification during distraction osteogenesis with recombinant human bone morphogenetic protein-7. J Bone Joint Surg Am 2003;85-A(suppl 3):124-130.
151. Friedlaender G. Clinical experience of osteogenic protein-1 (OP-1) in the repair of bone defects and fractures of long bones. In: Vukicevik S, Sampath KT, eds. Bone morphogenetic proteins: regeneration of bone and beyond. Basel, Switzerland: Birkhauser Verlag, 2004;157-163.
152. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 2002;27: S40-S48.
153. European Agency for the Evaluation of Medicinal Products. Eptotermin alfa. Scientific discussion. European Public Assessment Record. 2002. Available at: www.emea.europa.eu/humandocs/pdfs/EPAR/Osigraft/039301en6.pdf. Accessed Sep 10, 2007.
154. Kirker-Head C. Development and application of bone morphogenetic proteins for the enhancement of bone healing. J Orthop Traumatol 2005;6:1-9.